JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on August 30, 2006; DOI: 10.1124/jpet.106.107011


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.107011v1
319/2/980    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mantey, S. A.
Right arrow Articles by Jensen, R. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mantey, S. A.
Right arrow Articles by Jensen, R. T.


Received for publication April 27, 2006.
Revised August 25, 2006.
Accepted for publication August 28, 2006.

Identification of bombesin (Bn) receptor subtype-specific ligands: effect of N-methyl scanning, truncation, substitution and evaluation of putative reported selective ligands

Samuel A. Mantey 1, Nieves Gonzalez 1, Michael Schumann 1, Tapas K. Pradhan 1, Lin Shen 1, David H. Coy 2, Robert T. Jensen 1*

1 DDB, NIH 2 Tulane Univ. Health Sciences Center

* Address correspondence to: E-mail: robertj{at}bdg10.niddk.nih.gov

Abstract

Mammalian bombesin (Bn) receptors include the gastrin-releasing peptide receptor (GRPR), neuromedin B receptor (NMBR) and bombesin receptor subtype 3 (BRS-3). These receptors are involved in a variety of physiological/pathologic processes including thermoregulation, secretion, motility, chemotaxis and mitogenic effects on both normal and malignant cells. Tumors frequently overexpress these receptors and their presence is now used for imaging and receptor-mediated cytotoxicity. For these reasons there is an increased need to develop synthetic, selective receptor subtype specific ligands, especially agonists for these receptors. In this study we used a number of strategies to identify useful receptor subtype selective ligands including synthesizing new analogs (N-methyl-substituted constrained analogs, truncations, substitutions) in DTyr6,{beta}Ala11,Phe13,Nle14]Bn(6-14), which has high affinity for all Bn receptors and is metabolically stable, as well as completely pharmacologically characterized analogs recently reported to be selective for these receptors in [Ca2+]i assays. Affinities and potencies of each analog were determined for each human Bn receptor subtype. N-methyl substitutions in position 14,12,11,10,9,8 did not result in selective analogs and except in position 11 which markedly decreased affinity/potency. N terminal truncations or position 12 substitutions did not increase selectivity as previously reported by others. Of the four shortened analogs of [DPhe6,{beta}Ala11,Phe13,Nle14]Bn(6-14) reported to be potent selective BRS-3 ligands on [Ca2+]i assays, only Ac-Phe,Trp,Ala,His(tBzl),Nip,Gly,Arg-NH2 had moderate selectivity for hBRS-3, however it was less selective than previously reported Apa11 analogs, demonstrating these are still the most selective BRS-3 analogs available. However, both of these analogs should be useful templates to develop more selective BRS-3 ligands.


Key words: BRS-3, bombesin, bombesin receptors, gastrin-releasing peptide, neuromedin B, peptide structure-function


This article has been cited by other articles:


Home page
Pharmacol. Rev.Home page
R. T. Jensen, J. F. Battey, E. R. Spindel, and R. V. Benya
International Union of Pharmacology. LXVIII. Mammalian Bombesin Receptors: Nomenclature, Distribution, Pharmacology, Signaling, and Functions in Normal and Disease States
Pharmacol. Rev., March 1, 2008; 60(1): 1 - 42.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
N. Gonzalez, S. J. Hocart, S. Portal-Nunez, S. A. Mantey, T. Nakagawa, E. Zudaire, D. H. Coy, and R. T. Jensen
Molecular Basis for Agonist Selectivity and Activation of the Orphan Bombesin Receptor Subtype 3 Receptor
J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 463 - 474.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.